



Overview

We preserve native environment containing complement proteins for NK Engagers ex vivo activity assays

Click  to learn more

Click  for custom assays in solid tumors

Click  for custom assays in hematological malignancies



Vivia Experts in NK-Engager ex vivo Assays

Daratumumab ex vivo activity in >40 MM samples shows a high interpatient variability.





Figure 1. DR curves of Daratumumab ex vivo activity in >40 MM Samples.

Overview


We preserve native environment containing complement proteins for NK Engagers ex vivo activity assays

Click  to learn more

Click  for custom assays in solid tumors

Click  for custom assays in hematological malignancies

Killing activity on MM plasma cells > NK & T Cells
Kinetically faster convergence Tumor cells vs NK & T Cells



INCUBATION_TIME	Tumor					NKcell					Tcell				
	N	E _{max} %	E ₀ %	EC ₅₀	HILL	N	E _{max} %	E ₀ %	EC ₅₀	HILL	N	E _{max} %	E ₀ %	EC ₅₀	HILL
3	41	58.90	100.00	2.22	-2.00	36	76.83	100.00	3.12	-1.29	36	89.95	100.00	0.34	-1.19
6	25	54.60	100.00	2.73	-2.00	25	86.27	100.00	0.45	-0.65	25	95.33	100.00	0.48	-0.04
24	29	50.07	100.00	3.69	-1.36	29	86.29	100.00	1.85	-1.51	29	100.00	101.76	0.76	0.01


Figure 2. Mean Fits Dose Response Curves (N=25-41)

Overview

We preserve native environment containing complement proteins for NK Engagers ex vivo activity assays

Click  to learn more

Click  for custom assays in solid tumors

Click  for custom assays in hematological malignancies

Santiago Grisolia 2
28760 . Madrid . Spain
(+34) 91 129 3151
admin@viviabiotech.com
www.viviabiotech.com

Rituximab is more active against B Cells from RA than CLL




Figure 3. Rituximab Normalized Dose Response Curves Against B Cells from RA or CLL

- 👍 We preserve Native Environment:
 - Including RBCs and plasma, containing complement
- 👍 Daratumumab dose response curves in >40 samples reveal:
 - High interpatient variability
 - Killing activity on plasma cells > NK & T cells
 - Activity correlates with CD38 Expression
 - Activity Doesn't Correlate with NK/Tumor Cell Ratio
- 👍 Rituximab in >50 CLL vs RA Samples:
 - Rituximab is more active against B Cells from RA than CLL